<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The discovery of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) positivity in individuals who have never experienced <z:mp ids='MP_0005048'>thrombosis</z:mp> or <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> is not a rare event, and is one of the unresolved issues in the field of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>This paper focuses on primary prophylaxis for thrombotic events in aPL carriers </plain></SENT>
<SENT sid="2" pm="."><plain>In our view, patients with high risk aPL profiles and/or other <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, concomitant diagnosis of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and patients with an history of obstetric APS (OAPS) should be offered thromboprophylaxis </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> thromboprophylaxis with low-dose aspirin and hydroxychloroquine in aPL positive SLE patients should be prescribed both to prevent <z:mp ids='MP_0005048'>thrombosis</z:mp> and to avoid early organ damage </plain></SENT>
</text></document>